Related references
Note: Only part of the references are listed.Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
Guillermo Garcia-Manero
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
Amanda Cashen et al.
ANNALS OF HEMATOLOGY (2012)
Curcumin regulates airway epithelial cell cytokine responses to the pollutant cadmium
Jessica Rennolds et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Different Involvement of DNA Methylation and Histone Deacetylation in the Expression of Solute-Carrier Transporters in 4 Colon Cancer Cell Lines
Mika Ikehata et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2012)
Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
Uwe Platzbecker et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer
Jhanelle Gray et al.
CANCER BIOLOGY & THERAPY (2012)
A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer
M. G. Fakih et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma
Robert J. Amato et al.
CANCER INVESTIGATION (2012)
Progression of Prostate Carcinogenesis and Dietary Methyl Donors: Temporal Dependence
Shabana Shabbeer et al.
CANCER PREVENTION RESEARCH (2012)
Phase I/II study of decitabine in patients with myelodysplastic syndrome: A multi-center study in Japan
Yasuhiro Oki et al.
CANCER SCIENCE (2012)
A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2012)
Romidepsin for Cutaneous T-cell Lymphoma
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2012)
An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Nicola Tinari et al.
CURRENT CANCER DRUG TARGETS (2012)
Derivatives of Resveratrol: Potential Agents in Prevention and Treatment of Cardiovascular Disease
Ban-Feng Ruan et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Elena Talero et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Azacitidine A Review of its Use in the Management of Myelodysplastic Syndromes/Acute Myeloid Leukaemia
Gillian M. Keating
DRUGS (2012)
Curcumin and neurodegenerative diseases: a perspective
Altaf S. Darvesh et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Decitabine for acute myeloid leukemia
Peter W. Marks
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors
Annabelle L. Fonseca et al.
GENES CHROMOSOMES & CANCER (2012)
The impact of curcumin on breast cancer
Ganji Purnachandra Nagaraju et al.
INTEGRATIVE BIOLOGY (2012)
Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-alpha-induced oxidative stress, colitis and hepatotoxicity in mice
Souad Mouzaoui et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
Oscar Alcazar et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
Bryan J. Schneider et al.
INVESTIGATIONAL NEW DRUGS (2012)
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
Akira Fukutomi et al.
INVESTIGATIONAL NEW DRUGS (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Promoter methylation regulates cigarette smoke-stimulated cyclooxygenase-2 expression in esophageal squamous cell carcinoma
Xin Ying Meng et al.
JOURNAL OF DIGESTIVE DISEASES (2012)
Decitabine and Vorinostat Cooperate To Sensitize Colon Carcinoma Cells to Fas Ligand-Induced Apoptosis In Vitro and Tumor Suppression In Vivo
Dafeng Yang et al.
JOURNAL OF IMMUNOLOGY (2012)
Defining the Mechanism of Action and Enzymatic Selectivity of Psammaplin A against Its Epigenetic Targets
Matthias G. J. Baud et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
A dynamic multi-compartmental model of DNA methylation with demonstrable predictive value in hematological malignancies
Andrew P. McGovern et al.
JOURNAL OF THEORETICAL BIOLOGY (2012)
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
Reinhard Dummer et al.
LEUKEMIA & LYMPHOMA (2012)
LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism
Roberto Rosato et al.
LEUKEMIA RESEARCH (2012)
Histone methylation: a dynamic mark in health, disease and inheritance
Eric L. Greer et al.
NATURE REVIEWS GENETICS (2012)
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
Bret B. Friday et al.
NEURO-ONCOLOGY (2012)
Protective Effects of Curcumin on Amyloid-β-Induced Neuronal Oxidative Damage
Han-Chang Huang et al.
NEUROCHEMICAL RESEARCH (2012)
Histone deacetylase inhibitors (HDACIs). Structureuactivity relationships: history and new QSAR perspectives
Eleni Pontiki et al.
MEDICINAL RESEARCH REVIEWS (2012)
Methylation Markers of Early-Stage Non-Small Cell Lung Cancer
Kaie Lokk et al.
PLOS ONE (2012)
Inclusion Complex of Novel Curcumin Analogue CDF and β-Cyclodextrin (1:2) and Its Enhanced In Vivo Anticancer Activity Against Pancreatic Cancer
Prasad R. Dandawate et al.
PHARMACEUTICAL RESEARCH (2012)
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
V. Novotny-Diermayr et al.
BLOOD CANCER JOURNAL (2012)
Effect of novel water soluble curcumin derivative on experimental type-1 diabetes mellitus (short term study)
Mohamed T. Abdel Aziz et al.
DIABETOLOGY & METABOLIC SYNDROME (2012)
Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations
Manjeshwar Shrinath Baliga et al.
FOOD & FUNCTION (2012)
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
Ellen K. Ritchie
CLINICAL INTERVENTIONS IN AGING (2012)
Sirtuins and disease: the road ahead
Vincenzo Carafa et al.
FRONTIERS IN PHARMACOLOGY (2012)
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Chandra R. Tate et al.
BREAST CANCER RESEARCH (2012)
The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Jacob Peedicayil
CURRENT CLINICAL PHARMACOLOGY (2012)
Epigenetic Drug Discovery: Targeting DNA Methyltransferases
Jason M. Foulks et al.
JOURNAL OF BIOMOLECULAR SCREENING (2012)
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial
Myrna Candelaria et al.
ANNALS OF HEMATOLOGY (2011)
Chemosensitization of tumors by resveratrol
Subash C. Gupta et al.
RESVERATROL AND HEALTH (2011)
Safety of long-term treatment of HAM/TSP patients with valproic acid
Stephane Olindo et al.
BLOOD (2011)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L. Piekarz et al.
BLOOD (2011)
A pilot study of subcutaneous decitabine in β-thalassemia intermedia
Nancy F. Olivieri et al.
BLOOD (2011)
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
A. R. A. Razak et al.
BRITISH JOURNAL OF CANCER (2011)
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2011)
Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030
L. Lin et al.
BRITISH JOURNAL OF CANCER (2011)
Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky et al.
CANCER (2011)
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL
Vitaliy O. Kaminskyy et al.
CARCINOGENESIS (2011)
(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells
Vijayalakshmi Nandakumar et al.
CARCINOGENESIS (2011)
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer
Victoria L. Luchenko et al.
CELL CYCLE (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Epigenetic aberrations during oncogenesis
Maria Hatziapostolou et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
DNA hypermethylation as a chemotherapy target
Juan Ren et al.
CELLULAR SIGNALLING (2011)
Structure and Function of Mammalian DNA Methyltransferases
Renata Zofia Jurkowska et al.
CHEMBIOCHEM (2011)
Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Anastasios Stathis et al.
CLINICAL CANCER RESEARCH (2011)
Epigenetic-Based Therapies in Cancer Progress to Date
Sang-Hyun Song et al.
DRUGS (2011)
Hormonal Therapy Promotes Hormone-Resistant Phenotype by Increasing DNMT Activity and Expression in Prostate Cancer Models
Giovanni Luca Gravina et al.
ENDOCRINOLOGY (2011)
Decitabine, independent of apoptosis, exerts its cytotoxic effects on cell growth in melanoma cells
Qian-Ying Liu et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2011)
The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2′deoxycytidine (decitabine) are differentially regulated by cell cycle progression
Mazin Al-Salihi et al.
EPIGENETICS (2011)
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes
Thomas Prebet et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Entinostat for treatment of solid tumors and hematologic malignancies
Jeffrey Knipstein et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Mark Kirschbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas
Ganeshkumar Rajendran et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Epigenetic Regulation of Motor Neuron Cell Death through DNA Methylation
Barry A. Chestnut et al.
JOURNAL OF NEUROSCIENCE (2011)
Assessment of Objective Responses Using Volumetric Evaluation in Advanced Thymic Malignancies and Metastatic Non-small Cell Lung Cancer
Jeremy Force et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2011)
Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): Evolution on hypomethylating agent therapy
Christian Rose et al.
LEUKEMIA RESEARCH (2011)
Histone methyltransferases: a new class of therapeutic targets in cancer treatment?
Hassiba Chaib et al.
M S-MEDECINE SCIENCES (2011)
Synergistic apoptotic effect of Arabinoxylan rice bran (MGN-3/Biobran) and Curcumin (Turmeric) on human multiple myeloma cell line U266 in vitro
M. Ghoneum et al.
NEOPLASMA (2011)
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2011)
Impact of Curcumin, Raspberry Extract, and Neem Leaf Extract on Rel Protein-Regulated Cell Death/Radiosensitization in Pancreatic Cancer Cells
Jamunarani Veeraraghavan et al.
PANCREAS (2011)
Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines
Sabine Hagemann et al.
PLOS ONE (2011)
On the Evolutionary Origin of Eukaryotic DNA Methyltransferases and Dnmt2
Tomasz P. Jurkowski et al.
PLOS ONE (2011)
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
Ase Bratland et al.
RADIATION ONCOLOGY (2011)
Failure of Hypomethylating Agent-Based Therapy in Myelodysplastic Syndromes
Tapan M. Kadia et al.
SEMINARS IN ONCOLOGY (2011)
Epigenetic regulation of prostate cancer
Suyin P. Chin et al.
CLINICAL EPIGENETICS (2011)
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
Andrea Kuendgen et al.
CLINICAL EPIGENETICS (2011)
Sirtuin 1 (SIRT1): The Misunderstood HDAC
Walter Stuenkel et al.
JOURNAL OF BIOMOLECULAR SCREENING (2011)
Screening for Compounds That Modulate Epigenetic Regulation of the Transcriptome: An Overview
Richard M. Eglen et al.
JOURNAL OF BIOMOLECULAR SCREENING (2011)
The dicyclohexylamine salt of RG108 (N-phthalyl-L-tryptophan), a potential epigenetic modulator
Julie Braun et al.
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE (2010)
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
Monica Galli et al.
ANNALS OF HEMATOLOGY (2010)
Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors
Takayoshi Suzuki et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
Jiro Kikuchi et al.
BLOOD (2010)
Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585
Thorsten Stuehmer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
Daniela Buglio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21
Deok-Soo Son et al.
CANCER BIOLOGY & THERAPY (2010)
SIRT3 Is a Mitochondria-Localized Tumor Suppressor Required for Maintenance of Mitochondrial Integrity and Metabolism during Stress
Hyun-Seok Kim et al.
CANCER CELL (2010)
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer
Yi-kang Shi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
New Anacardic Acid-Inspired Benzamides: Histone Lysine Acetyltransferase Activators
Jose A. Souto et al.
CHEMMEDCHEM (2010)
Solving the Dnmt2 enigma
Matthias Schaefer et al.
CHROMOSOMA (2010)
Emerging Anticancer Therapeutic Targets and the Cardiovascular System Is There Cause for Concern?
Xuyang Peng et al.
CIRCULATION RESEARCH (2010)
Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: A Case Series Illustrating Utility in Clinical Practice
Amitabha Mazumder et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
POSSIBLE LINKS BETWEEN INTESTINAL PERMEABLITY AND FOOD PROCESSING: A POTENTIAL THERAPEUTIC NICHE FOR GLUTAMINE
Jean Robert Rapin et al.
CLINICS (2010)
Molecular and Enzymatic Profiles of Mammalian DNA Methyltransferases: Structures and Targets for Drugs
F. Xu et al.
CURRENT MEDICINAL CHEMISTRY (2010)
RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage
Matthias Schaefer et al.
GENES & DEVELOPMENT (2010)
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance
Wenlin Shao et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Breast Cancer Epigenetics: From DNA Methylation to microRNAs
Juergen Veeck et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2010)
Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor
David Moffat et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
Gregory A. Otterson et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents
Sameer Mirza et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2010)
SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
Veronica Novotny-Diermayr et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade
Victoria El-Khoury et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Anne Hansen Ree et al.
LANCET ONCOLOGY (2010)
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor
Wei-Gang Tong et al.
LEUKEMIA RESEARCH (2010)
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation
E. Borbone et al.
ONCOGENE (2010)
Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+Cell Infection
Nancie M. Archin et al.
PLOS ONE (2010)
Combination of Suberoylanilide Hydroxamic Acid and Ritonavir is Effective Against Renal Cancer Cells
Akinori Sato et al.
UROLOGY (2010)
Phase 2 study of sodium phenylbutyrate in ALS
Merit E. Cudkowicz et al.
AMYOTROPHIC LATERAL SCLEROSIS (2009)
The Anticancer Agent Chaetocin Is a Competitive Substrate and Inhibitor of Thioredoxin Reductase
Jennifer D. Tibodeau et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
Chemical mechanisms of histone lysine and arginine modifications
Brian C. Smith et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2009)
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
Warren Fiskus et al.
BLOOD (2009)
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Tamer E. Fandy et al.
BLOOD (2009)
Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells
Amel Baya Bouzar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
Kristie A. Blum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation
Jharna Datta et al.
CANCER RESEARCH (2009)
The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors
Astrid Spannhoff et al.
CHEMMEDCHEM (2009)
Molecular Modeling and Molecular Dynamics Studies of Hydralazine with Human DNA Methyltransferase 1
Narender Singh et al.
CHEMMEDCHEM (2009)
Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Adi I. Daud et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros et al.
CLINICAL CANCER RESEARCH (2009)
JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
Janine Arts et al.
CLINICAL CANCER RESEARCH (2009)
Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Tamer E. Fandy
CURRENT MEDICINAL CHEMISTRY (2009)
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL/lpr-/- murine model of autoimmune lymphoproliferative syndrome (ALPS)
Kennichi C. Dowdell et al.
EXPERIMENTAL HEMATOLOGY (2009)
Sirtuin inhibitors
Francisco J. Alcain et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead
Antonello Mai et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Cancer treatment of the future: Inhibitors of histone methyltransferases
Astrid Spannhoff et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
SIRT1, Is It a Tumor Promoter or Tumor Suppressor?
Chu-Xia Deng
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2009)
The conserved role of sirtuins in chromatin regulation
Alejandro Vaquero
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2009)
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Robert P. Whitehead et al.
INVESTIGATIONAL NEW DRUGS (2009)
Vorinostat in solid and hematologic malignancies
David Siegel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
M. Cecilia Crisanti et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis
B. Stamatopoulos et al.
LEUKEMIA (2009)
Protein methyltransferases as a target class for drug discovery
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
How does SIRT1 affect metabolism, senescence and cancer?
Christopher L. Brooks et al.
NATURE REVIEWS CANCER (2009)
Epigenetics, DNA Methylation, and Chromatin Modifying Drugs
Moshe Szyf
Annual Review of Pharmacology and Toxicology (2008)
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Nagma Khan et al.
BIOCHEMICAL JOURNAL (2008)
2-trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors
Philip Jones et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells
Anna Scuto et al.
BLOOD (2008)
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Guillermo Garcia-Manero et al.
BLOOD (2008)
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
L. Nolan et al.
BRITISH JOURNAL OF CANCER (2008)
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Jennifer S. Carew et al.
CANCER LETTERS (2008)
Induction of Pluripotent Stem Cells from Mouse Embryonic Fibroblasts by Oct4 and Klf4 with Small-Molecule Compounds
Yan Shi et al.
CELL STEM CELL (2008)
Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities
Jose A. Souto et al.
CHEMMEDCHEM (2008)
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)
Nataly Tarasenko et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
Lia Gore et al.
CLINICAL CANCER RESEARCH (2008)
Clinical and molecular responses in lung cancer patients receiving Romidepsin
David S. Schrump et al.
CLINICAL CANCER RESEARCH (2008)
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia
Rebecca B. Klisovic et al.
CLINICAL CANCER RESEARCH (2008)
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (Romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes
Virginia M. Klimek et al.
CLINICAL CANCER RESEARCH (2008)
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Leigh Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Alan Kozikowski et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Histone deacetylase inhibitors in cancer therapy: New compounds and clinical update of benzamide-type agents
Oscar Moradei et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2008)
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
Peter Gimsing et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
D. G. Binion et al.
GUT (2008)
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Susan C. Modesitt et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Structural origin of selectivity in class II-selective histone deacetylase inhibitors
Guillermina Estiu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial
Shanu Kohli Kurd et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Marielle Fournel et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
The use of diversity profiling to characterize chemical modulators of the histone deacetylases
Leonard Blackwell et al.
LIFE SCIENCES (2008)
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Jeffrey A. Simon et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Histone acetylation and chromatin signature in stem cell identity and cancer
Vivek Shukla et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Depsipeptide (FK228) inhibits growth of human prostate cancer cells
Ming-Tsung Lai et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
Demethylating agent 5-aza-2 '-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin
Donghao Shang et al.
UROLOGY (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin
Rodwell Mabaera et al.
BLOOD (2008)
A therapeutic role for sirtuins in diseases of aging?
C. H. Westphal et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Histone deacetyllase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondriall and Fas (Cd95) signalling in head and neck squamous carcinorna cells
Ann M. Gillenwater et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage
Rentian Feng et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Sodium phenylbutyrate in Huntington's disease: A dose-finding study
Penelope Hogarth et al.
MOVEMENT DISORDERS (2007)
Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response
Laurence Lagneaux et al.
EXPERIMENTAL HEMATOLOGY (2007)
Histone deacetylase inhibitors: Overview and perspectives
Milos Dokmanovic et al.
MOLECULAR CANCER RESEARCH (2007)
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
M. Candelaria et al.
ANNALS OF ONCOLOGY (2007)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
Sirtuins: critical regulators at the crossroads between cancer and aging
L. R. Saunders et al.
ONCOGENE (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Sirtuin functions in health and disease
Hiroyasu Yamamoto et al.
MOLECULAR ENDOCRINOLOGY (2007)
Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line
E. Rabizadeh et al.
LEUKEMIA RESEARCH (2007)
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Madeleine Duvic et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Functional differences in epigenetic modulators - Superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies
Alan P. Kozikowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis
Nina Raver-Shapira et al.
MOLECULAR CELL (2007)
Histone deacetylase inhibitors in cancer therapy
Walid K. Rasheed et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy
Jose A. Karam et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
trans-2-phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1
Dawn M. Z. Schmidt et al.
BIOCHEMISTRY (2007)
Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress
Crescent R. Isham et al.
BLOOD (2007)
The mammalian epigenome
Bradley E. Bernstein et al.
CELL (2007)
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
Stefan Kubicek et al.
MOLECULAR CELL (2007)
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
Qun Zhou et al.
CANCER BIOLOGY & THERAPY (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
Dietary polyphenols may affect DNA methylation
Mingzhu Fang et al.
JOURNAL OF NUTRITION (2007)
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
Claudia Arce et al.
PLOS ONE (2006)
Altered sirtuin expression is associated with node-positive breast cancer
N. Ashraf et al.
BRITISH JOURNAL OF CANCER (2006)
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura
David S. Schrump et al.
CLINICAL CANCER RESEARCH (2006)
A phase II study of depsipeptide in refractory metastatic renal cell cancer
Walter M. Stadler et al.
CLINICAL GENITOURINARY CANCER (2006)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
Patricia Maiso et al.
CANCER RESEARCH (2006)
Histone modifications: signalling receptors and potential elements of a heritable epigenetic code
KP Nightingale et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2006)
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study
E Winquist et al.
INVESTIGATIONAL NEW DRUGS (2006)
Synthesis and in vitro evaluation of biotinylated RG108: A high affinity compound for studying binding interactions with human DNA methyltransferases
E Schirrmacher et al.
BIOCONJUGATE CHEMISTRY (2006)
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications
Min Gyu Lee et al.
CHEMISTRY & BIOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
The epigenetic progenitor origin of human cancer
AP Feinberg et al.
NATURE REVIEWS GENETICS (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
5-Aza-2′-deoxycytidine induces retinoic acid receptor-β2 demethylation and growth inhibition in esophageal squamous carcinoma cells
ZM Liu et al.
CANCER LETTERS (2005)
Human histone demethylase LSD1 reads the histone code
F Forneris et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids
WJ Lee et al.
MOLECULAR PHARMACOLOGY (2005)
MicroRNAs in vertebrate development
BD Harfe
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9
D Greiner et al.
NATURE CHEMICAL BIOLOGY (2005)
Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases
B Brueckner et al.
CANCER RESEARCH (2005)
Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice
H Ryu et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs
QJ Lu et al.
JOURNAL OF IMMUNOLOGY (2005)
Mechanism of human SIRT1 activation by resveratrol
MT Borra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease
G Gardian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Cardiac histone acetylation - therapeutic opportunities abound
TA McKinsey et al.
TRENDS IN GENETICS (2004)
Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma
SB Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases
XJ Yang
NUCLEIC ACIDS RESEARCH (2004)
MicroRNAs: Genomics, biogenesis, mechanism, and function
DP Bartel
CELL (2004)
Epigenetic gene silencing in acute promyelocytic leukemia
R Villa et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells
A Burgess et al.
ONCOGENE (2004)
Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol
S Fulda et al.
ONCOGENE (2004)
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer
T Reid et al.
LUNG CANCER (2004)
Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression
K Balasubramanyam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription
K Balasubramanyam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases
JR Somoza et al.
STRUCTURE (2004)
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells
DM Lucas et al.
LEUKEMIA (2004)
Epigenetics in human disease and prospects for epigenetic therapy
G Egger et al.
NATURE (2004)
Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor α (ER) in ER-negative human breast cancer cell lines
L Yan et al.
CANCER BIOLOGY & THERAPY (2003)
Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300
M Cebrat et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
Small molecule modulators of histone acetyltransferase p300
K Balasubramanyam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly
DJ Stewart et al.
ANNALS OF ONCOLOGY (2003)
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation
SJ Haggarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks
AJ David et al.
INVESTIGATIONAL NEW DRUGS (2003)
Effects of 5-aza-2 '-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease
Y Saunthararajah et al.
BLOOD (2003)
Mechanisms of disease: Rules for making human tumor cells.
WC Hahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The fundamental role of epigenetic events in cancer
PA Jones et al.
NATURE REVIEWS GENETICS (2002)
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor
L Di Croce et al.
SCIENCE (2002)
DNA methyltransferase inhibitors - state of the art
J Goffin et al.
ANNALS OF ONCOLOGY (2002)
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen
CJ Phiel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Histone deacetylase as a therapeutic target
OH Krämer et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2001)
Histone methylation versus histone acetylation: new insights into epigenetic regulation
JC Rice et al.
CURRENT OPINION IN CELL BIOLOGY (2001)
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
CM Galmarini et al.
LEUKEMIA (2001)
DNA methylation, methyltransferases, and cancer
KD Robertson
ONCOGENE (2001)
DNA methylation in health and disease
KD Robertson et al.
NATURE REVIEWS GENETICS (2000)
Acetylation of histones and transcription-related factors
DE Sterner et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2000)
The language of covalent histone modifications
BD Strahl et al.
NATURE (2000)
HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF
OD Lau et al.
MOLECULAR CELL (2000)
Share Paper
